In an attempt to study the mode-of-action of CypA, we wanted to exploit the possibility to interfere with this protein pharmacologically by using DEBIO-025, a compound that shows promise in clinical trials for the treatment of chronic hepatitis C [42]. The gene discussed is PPIA; the disease is chronic hepatitis C virus infection.